MORGANTOWN, W.Va. – The Therapeutic Development Network (TDN), the industry leader in the development of cystic fibrosis treatments, has ranked the WVU Medicine adult and pediatric cystic fibrosis programs 13th out of 90 TDN centers for interventional study enrollment and seventh out of 59 centers for observational studies.
“This is tremendous effort by our research coordinator and the entire adult and pediatric cystic fibrosis teams,” Kathryn Moffett, M.D., WVU Medicine infectious disease specialist and cystic fibrosis center director, said. “Enrolling patients into clinical studies is challenging and time consuming. We wouldn’t be able to develop such a reputation in the industry without our team’s dedication.”
Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.
The Cystic Fibrosis Therapeutics Development Network is the largest cystic fibrosis clinical trials network in the world. The organization brings together experts from across the country to evaluate the safety and effectiveness of new CF therapies through clinical studies. It currently has 125 member organizations.
“Pharmaceutical companies that have a new cystic fibrosis drug go through the TDN to conduct clinical trials,” Dr. Moffett said. “TDN members have proven they have the necessary facilities, equipment, and staff to conduct clinical trials properly. This expedites the process of bringing new treatments to the market.”
For more information on CF care at WVU Medicine, visit https://childrens.wvumedicine.org/services/specialty-care/cystic-fibrosis.